Results 191 to 200 of about 935,849 (402)
Expert Perspective: How, When, and Why to Potentially Stop Antiresorptive Drugs in Osteoporosis
Arthritis &Rheumatology, EarlyView.Osteoporosis is a chronic disease, and antiresorptive treatments are often continued for many years. Despite their established efficacy in reducing fracture risk, the most commonly used antiresorptive treatments, bisphosphonates and denosumab, have short‐ and long‐term risks that, coupled with their benefits and other unique characteristics, influence ...Giovanni Adami, Kenneth G. Saagwiley +1 more sourceProcalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.
Cochrane Database of Systematic Reviews, 2017 P. Schuetz, Yannick Wirz, Ramon Sager, M. Christ-Crain, D. Stolz, M. Tamm, L. Bouadma, C. Luyt, M. Wolff, J. Chastre, F. Tubach, K. B. Kristoffersen, O. Burkhardt, T. Welte, S. Schroeder, V. Nobre, Long Wei, H. Bucher, N. Bhatnagar, D. Annane, K. Reinhart, A. Branche, P. Damas, M. Nijsten, D. D. de Lange, R. Deliberato, Stella S S Lima, V. Maravić-Stojković, A. Verduri, B. Cao, Y. Shehabi, A. Beishuizen, J. Jensen, C. Corti, J. V. van Oers, A. Falsey, E. D. de Jong, C. F. Oliveira, B. Beghé, M. Briel, B. Mueller +40 moresemanticscholar +1 more sourceEfficacy and Safety of ABBV‐154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo‐Controlled Trial
Arthritis &Rheumatology, Accepted Article.Objective
Despite availability of biologics and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) to treat rheumatoid arthritis (RA), many patients do not experience optimized disease control. Glucocorticoids are effective but have safety risks.Frank Buttgereit, Atul Singhal, Alan Kivitz, Edit Drescher, Yoshinori Taniguchi, Rosalía Martínez Pérez, Jaclyn Anderson, Ronilda D'Cunha, Weihan Zhao, Nicholas DeVogel, Julie Parmentier, Romy Christmann, Dilek Arikan, Howard Amital +13 morewiley +1 more sourceMortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017
The Lancet Respiratory Medicine, 2019 C. Troeger, B. Blacker, I. Khalil, Stephanie R M Zimsen, Samuel B. Albertson, D. Abate, Jemal Abdela, Tara Ballav Adhikari, S. Aghayan, S. Agrawal, A. Ahmadi, Amani Nidhal Aichour, Ibtihel Aichour, Miloud Taki Eddine Aichour, A. Al-Eyadhy, Rajaa Al-Raddadi, Fares Alahdab, K. Alene, S. Aljunid, N. Alvis-Guzmán, N. Anber, Mina Anjomshoa, C. Antonio, O. Aremu, Hagos T. Atalay, S. Atique, E. Attia, Euripide Avokpaho, A. Awasthi, A. Babazadeh, H. Badali, A. Badawi, J. Banoub, A. Barać, Q. Bassat, Neeraj Bedi, A. Belachew, D. Bennett, Krittika Bhattacharyya, Z. Bhutta, Ali Bijani, F. Carvalho, C. Castañeda-Orjuela, D. Christopher, L. Dandona, R. Dandona, Anh Kim Dang, A. Daryani, M. G. Degefa, F. M. Demeke, M. Dhimal, Shirin Djalalinia, D. Doku, M. Dubey, E. Dubljanin, Eyasu Ejeta Duken, Dumessa Edessa, M. El Sayed Zaki, H. Fakhim, E. Fernandes, F. Fischer, L. Flor, Kyle Foreman, Teklu Gebrehiwo Gebremichael, D. Geremew, K. Ghadiri, A. Goulart, Jingwen Guo, G. H. Ha, G. B. Hailu, Arvin Haj-Mirzaian, A. Haj-Mirzaian, S. Hamidi, H. Y. Hassen, C. L. Hoang, N. Horita, M. Hostiuc, S. Irvani, Ravi Prakash Jha, J. Jonas, Amaha Kahsay, A. Karch, A. Kasaeian, T. Kassa, A. Kefale, Y. Khader, E. Khan, G. Khan, Md Nuruzzaman Khan, Y. Khang, A. Khoja, J. Khubchandani, R. Kimokoti, A. Kisa, L. Knibbs, S. Kochhar, S. Kosen, P. Koul, A. Koyanagi, B. Kuate Defo, G. Kumar, D. Lal, Prabhat Lamichhane, C. T. Leshargie, M. Levi, Shanshan Li, Erlyn K Macarayan, M. Majdan, Varshil Mehta, A. Melese, Z. Memish, D. T. Mengistu, T. Meretoja, T. Meštrović, Bartosz Miazgowski, G. Milne, B. Milošević, E. Mirrakhimov, B. Moazen, K. Mohammad, S. Mohammed, L. Monasta, L. Morawska, Seyyed Meysam Mousavi, O. Muhammed, S. Murthy, G. Mustafa, A. Naheed, H. Nguyen, N. B. Nguyen, S. H. Nguyen, T. H. Nguyen, M. I. Nisar, M. Nixon, F. Ogbo, A. Olagunju, T. Olagunju, Eyal Oren, J. Ortiz, M. P A, S. Pakhalé, Shanti Patel, Deepak Paudel, D. Pigott, M. Postma, M. Qorbani, Anwar Rafay, A. Rafiei, V. Rahimi-Movaghar, R. Rai, M. S. Rezai, Nicholas Roberts, L. Ronfani, S. Rubino, Saeed Safari, S. Safiri, Z. Saleem, E. Sambala, A. Samy, M. Šantrić Milićević, B. Sartorius, S. Sarvi, M. Savic, M. Sawhney, S. Saxena, S. Seyedmousavi, M. Shaikh, M. Sharif, A. Sheikh, M. Shigematsu, David L. Smith, R. Somayaji, J. Soriano, C. Sreeramareddy, M. Sufiyan, M. Temsah, B. Tessema, Mebrahtu Teweldemedhin, M. Tortajada-Girbés, B. Tran, Khanh B. Tran, Afewerki Gebremeskel Tsadik, K. Ukwaja, I. Ullah, T. Vasankari, G. Vu, Fiseha Wadilo Wada, Yasir Waheed, T. West, C. Wiysonge, Ebrahim M. Yimer, N. Yonemoto, Z. Zaidi, T. Vos, Stephen S. Lim, C. Murray, A. Mokdad, Simon Iain Hay, R. Reiner +198 moresemanticscholar +1 more sourceA Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis
Arthritis &Rheumatology, EarlyView.Objective
To compare the efficacy of abatacept to placebo for the treatment of relapsing, nonsevere granulomatosis with polyangiitis (GPA). Methods
In this multicenter trial, eligible patients with relapsing, nonsevere GPA were randomized to receive abatacept 125 mg subcutaneously once a week or placebo, both together with prednisone 30 mg/day (or ...Carol A. Langford, Nader Khalidi, Jason Springer, Marcia Friedman, Bernhard Hellmich, Christian Pagnoux, Natasha Dehghan, Ora Gewurz‐Singer, Curry L. Koening, Yih Chang Lin, Paul A. Monach, Larry W. Moreland, Aurore Fifi‐Mah, Oliver Flossmann, Lindsy J. Forbess, Peter Lanyon, Eamonn Molloy, Ulrich Specks, Robert Spiera, Elaine Yacyshyn, Carol A. McAlear, Cristina Burroughs, Rachel B. Jones, Rennie L. Rhee, Rula Hajj‐Ali, Kenneth J. Warrington, David Cuthbertson, Jeffrey P. Krischer, David Jayne, Peter A. Merkel, for the Vasculitis Clinical Research Consortium and the European Vasculitis Society, Eric Stratton, Marcin Trojanowski, Chris Zammitti, Jessica Ziemek, Javier Ache, Marianne Bernardo, Bryan Gonzalez, Mariko Ishimori, Bonnie Paul, Mahbuba Tusty, Swamy Venuturupalli, Daniel Wallace, Michael Weisman, Debora Bork, Tiffany Clark, Sonya Crook, Kathleen Gartner, Lori Strozniak, Elizabeth Kisela, Marcia Leon, Loretta Williams, Jeff Negrey, Hannah Thome, Andrew Wiecek, Beemnet Amdemicael, Emily Bakaj, Aliza Bloostein, Annel Fernandez, Chris Hatzis, Lindsay Lally, Misbah Baqir, Cynthia Beinhorn, Shannon Daley, Sue Donlinger, Samantha Fatis, Yeoniee Kim, Matthew Koslow, Matthew J. Koster, Kathleen Mieras, Tobias Peikert, Michael Stachowitz, Gwen E. Thompson, Medius Klinik Kirchheim, Nicole Hollinger, Nina Kempiners, Hartmut Mahrhofer, Anke Reichelt de Tenorio, Bastian Walz, Banita Aggarwal, Simon Carette, Nazrana Haq, Samyukta Jagadeesh, Suneet Khurana, Judy Vendramini, Amanda Butler, Mithun Chakravorty, Paige Draper, Cattleya Godsave, Marie‐Josèphe Pradère, Megan Rutter, Alan Thomas, Rebekah Alexander, Cong‐Qiu Chu, Daniela Ghetie, Amy Jeon, Michelle Jin, Kim Phung Nguyen, Brenda Olmos, Kelly Peel, Rosy Quinn, Cailin Sibley, Mayamol Joseph, Deepa Thapa, Sandra Messier, Diane Robins, Jayamarx Jayaraman, Kam Shojania, Richard Conway, Kathy Brickell, Phil Gallagher, Alison Clifford, Sylvia Gaucher, Ainslie Hildebrand, Karen Martins, Breanne Stewart, Stephen Chaudary, Namneet Sandhu, Stephen Williams, Karen Dahlsveen, Seerapani Gopaluni, Cecilia Matara, Mark McClure, Rona Smith, Amrita Bath, Leslie Glasco, Theresa Howard, Caitlin McMillian, Na Yu, Mingcai Zhang, Ruba Kado, Emily Lewis, W. Joseph McCune, Emily Siegwald, Jennifer Sylvester, Naomi Amudala, Kathryn Doyle, Matthew MacDonald, Leah Madden, Brian Rice, Antoine Sreih, Sally Thompson, Laurie Hope, Kimberly Liang, Douglas Lienesch, Niveditha Mohan, Kelly Reckley, John Carter, Gail Lewis, Michelle Orzechowski, Martha Finco, Jennifer Godina, Jessica Gonzalez, Julieanne Hall, Nereida Ortez, Gopi Penmetsa +155 morewiley +1 more sourceB cells and systemic sclerosis interstitial lung disease
Arthritis &Rheumatology, Accepted Article.Interstitial lung disease is an important complication of systemic sclerosis (SSc‐ILD) with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to FDA‐approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of interstitial lung diseases of other systemic autoimmune ...Nina Goldman, Voon Ong, Christopher Denton +2 morewiley +1 more source
